Test Price
2,800 AED✅ Home Collection Available
EFHC2 Gene X‑Linked Mental Retardation Genetic Test (Next‑Generation Sequencing) in UAE | 2800 AED
Executive Summary & Core Metrics
Clinically validated next‑generation sequencing (NGS) assay targeting the EFHC2 gene with 99.9% analytical sensitivity for all coding exons. Delivered via ISO‑certified temperature‑controlled cold‑chain home collection across all Emirates, this test identifies pathogenic variants associated with X‑linked intellectual disability, enabling precise molecular diagnosis, carrier screening, and family‑centred neurological care. UAE‑licensed phlebotomists perform whole‑blood collection; turnaround time is 3–4 weeks; direct insurance billing and same‑day tele‑guidance are included. The assay is accredited under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and fully compliant with UAE federal data‑protection and health‑information frameworks.
- Price: 2,800 AED
- Turnaround Time: 3–4 weeks
- Sample Type: Peripheral whole blood (DNA‑stabilising tube)
- Methodology: Next‑generation sequencing – full gene analysis
- Analytical Sensitivity: >99.9% for coding‑region variants
Test Overview & Methodology
The EFHC2 Genetic Test interrogates the complete coding region of the EFHC2 gene using high‑coverage NGS, outperforming traditional Sanger‑based single‑exon analysis by simultaneously detecting single‑nucleotide variants, small insertions and deletions, and copy‑number alterations in a single workflow. This comprehensive approach delivers definitive molecular confirmation of X‑linked mental retardation when clinical features overlap with other neurodevelopmental disorders, reducing diagnostic odyssey time and enabling earlier intervention.
| Feature | Our EFHC2 NGS Test | Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next‑Generation Sequencing – full gene (all exons) | Sanger sequencing – single exon or hotspot only |
| Variant Detection | SNVs, indels, CNVs across all coding exons | Restricted to targeted region; large deletions missed |
| Turnaround Time | 3–4 weeks | 6–8 weeks (often outsourced) |
| Clinical Sensitivity | >99.9% for EFHC2 coding variants | ~95% (deep intronic and copy‑number changes missed) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics | DHA Registration ID: 9294403) advises: “A positive EFHC2 variant must be correlated with the neurodevelopmental phenotype and a three‑generation pedigree. This NGS assay is a high‑precision diagnostic adjunct, not a stand‑alone confirmation. Every result warrants collaborative review with a clinical geneticist and a paediatric neurologist to shape an individualised care plan.”
Important Clinical Advisory
Genetic test results must not be used as a sole basis for altering ongoing therapies. Maintain all current neurological and behavioural treatments unless explicitly adjusted by your managing physician following a comprehensive clinical evaluation. Always consult your doctor before making any changes to prescribed medication.
Exclusion Criteria & Urgent Clinical Indicators
- Acute febrile illness or active systemic infection – reschedule collection until resolved.
- Known bleeding diathesis or severe anaemia – home phlebotomy requires prior individual assessment by the attending physician.
- Inability to provide informed consent; for minors, guardian consent is mandatory under UAE federal law.
- Emergency red flags: sudden loss of developmental milestones, intractable seizures, or signs of raised intracranial pressure require immediate emergency department evaluation, not a scheduled genetic blood draw.
- Current anticoagulant therapy – disclose to the logistics team at least 48 hours before collection.
Patient FAQ & Clinical Guidance
1. What is the accuracy of the EFHC2 NGS test for diagnosing X‑linked intellectual disability?
With greater than 99.9% analytical sensitivity across all coding exons, this NGS assay reliably detects point mutations, small insertions and deletions, and copy‑number changes in the EFHC2 gene. Clinical interpretation is performed by board‑certified molecular geneticists referencing current ClinVar and ACMG guidelines, yielding a definitive molecular diagnosis when the clinical presentation is consistent.
2. What preparation is needed before the test, and is genetic counselling mandatory?
A pre‑test genetic counselling session is mandatory to construct a three‑generation pedigree, explain X‑linked inheritance patterns, and obtain truly informed consent. Patients should provide all available neurological reports, brain MRI images, and prior genetic test results. Fasting is not required; adequate hydration is recommended. For minors, the presence of both parents is strongly advised.
3. How is home collection performed and is the sample stable during transport?
A DHA‑licensed phlebotomist collects whole blood into a specialised DNA‑stabilising tube, which is immediately placed in a validated 2–8°C cold‑chain carrier; DNA remains intact for up to 14 days. For remote areas, a dried blood spot on an FTA card is accepted. The entire process follows ISO 9001:2015 quality protocols, ensuring sample integrity from vein to analyser. Same‑day or next‑day collection is available across Dubai, Abu Dhabi, Sharjah, and the Northern Emirates between 8 AM and 11 PM.
UAE Regulatory & Data Privacy Adherence
All genetic testing at DNA Labs UAE is conducted in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and informed consent procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. The facility is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License Number 1143. Patient data is encrypted, access‑controlled, and never shared with third parties without explicit consent. For insurance verification, appointment scheduling, or clinical guidance, contact us via WhatsApp or phone at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | EFHC2 Gene X‑Linked Mental Retardation Genetic Test (Next‑Generation Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (DNA‑stabilising tube) or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coding‑region analysis |
| ICD-10-CM Code | F78 |
| LOINC Code | 82460-1 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians